Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
09688 ZAI LAB
RTNominal up12.700 +0.060 (+0.475%)
Others

17/12/2021 14:48

Zai Lab (09688) gets new drug application approval

[ET Net News Agency, 17 December 2021] Zai Lab Limited (09688) said the China National
Medical Products Administration (NMPA) has approved a new drug application for NUZYRA
(omadacycline) for the treatment of community-acquired bacterial pneumonia and acute
bacterial skin and skin structure infections.
NUZYRA was approved as a Category 1 innovative drug by the NMPA and is locally
manufactured in China. It is its fourth product approved over the last 24 months. (RC)

Back to Others

Remark: Real time quote last updated: 26/04/2024 11:42
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.